Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596239 | 1.00 | HCRTR1 (0.45) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL4917611 | 0.94 | USP30 (0.43) | HCRTR1HCRTR2ALDH1A1USP30GPR119 | |
| SCHEMBL4917620 | 0.94 | USP30 (0.43) | HCRTR1HCRTR2ALDH1A1USP30GPR119 | |
| SCHEMBL3859454 | 0.89 | SCD5 (0.48) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL3852498 | 0.89 | SCD5 (0.48) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL3916612 | 0.86 | HCRTR1 (0.53) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL3916610 | 0.86 | HCRTR1 (0.53) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL3852302 | 0.85 | HCRTR1 (0.50) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL3852298 | 0.85 | HCRTR1 (0.50) | HCRTR1HCRTR2ALDH1A1USP30LMNA | |
| SCHEMBL17063835 | 0.85 | HCRTR1 (0.57) | HCRTR1HCRTR2ALDH1A1USP30LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008117051-A1 | S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | ASRAZENECA (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1871771-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006109026-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | IGF1R, IGFBP1, IRS1 | HCRTR1 4468/4885HCRTR2 4336/4885ALDH1A1 1905/4885 |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | UGT2B7, UGT1A7, CYP3A7 | HCRTR1 4533/4885HCRTR2 4522/4885ALDH1A1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.